# Adversarial review - hygiene-hypothesis

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14.
**Level before:** Gamma (Mechanistically plausible, partial system support), Moderate confidence.
**Level after:** Gamma (Mechanistically plausible, partial system support), Moderate confidence. Unchanged.

## Summary

| Severity | Count |
|---|---|
| Critical | 0 |
| Major | 0 |
| Minor | 2 |
| Editorial | 1 |

PMIDs verified: 63/63 against PubMed metadata, 0 failures, no retraction or expression-of-concern flags.
Load-bearing claims spot-checked: 12, all consistent with the cited abstracts, including the exact ORBEX hazard ratio and confidence interval.
Validator after editing: PASS (0 fail, 0 warn, 31 pass), matching the counts in the package's own validation-report.json.

## Findings

| ID | Severity | Location | Correction |
|---|---|---|---|
| D1 | Minor | M/S/D prose and score card divergence | Contested divergence given its required artifact: the two competing framings and why no single implied level applies |
| D2 | Minor | Consensus and original-source reconciliation | "hazard ratio1.16, confidence interval0.82-1.64" and "over14days" corrected to spaced forms; the ORBEX values re-verified against the primary abstract first |
| D3 | Editorial | REFERENCES item 35 | "DOI: ." corrected to "DOI: none indexed." (PubMed indexes no DOI for PMID 9179425) |

## Rejected findings

Gamma for SC3 despite two positive randomized eczema trials - the trials supply a defined product and do not perturb the registered general-deprivation exposure, so cap precedence keeps them at SC2; aggregation correct, including that SC2's Epsilon is scope-restricted and cannot set the headline under scope-matched; Epsilon rather than Delta for SC2 (the boundary is mapped, not untested); role of mechanism as reinforcing or stabilizing factor; Momentum "Mechanistic only" with a properly named artifact; Stability "Stable"; timeline years match their records; the separation of LEAP and EAT as antigen-tolerance rather than microbial evidence.

## Approval

Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14.

## Addendum - coordinator-flagged systematic artifacts (same pass, 2026-10-14)

Four artifacts reported by other groups mid-pass were checked in this case. Findings added:

| ID | Severity | Location | Correction |
|---|---|---|---|
| D4 | Minor | score card final_score.confidence_rationale | access depth dropped as a determinant; High-band re-test recorded; band holds at Moderate |

Also checked and rejected:

- Confidence band re-tested against the High text after removing access depth: short trials diverging by strain and endpoint, with several reports sharing one parent randomization and overlapping cohorts, is the Moderate text; band holds
- Coordinator-flagged Consensus-splice artifacts do not apply: this case is not a 2026-10-09 revised edition; its Consensus reconciliation section is original to the review
- Best-supported rival renderer defect: models_evaluated[0] here is M2, is_nominal false, rank 1, with the nominal at rank 3; the prose names the rival correctly

Revised severity counts: Critical 0, Major 0, Minor 3, Editorial 1. The level and confidence remain unchanged, and the validator still passes.